362 related articles for article (PubMed ID: 18784280)
1. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
2. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.
Rebello S; Compain S; Feng A; Hariry S; Dieterich HA; Jarugula V
J Clin Pharmacol; 2011 Nov; 51(11):1549-60. PubMed ID: 21406600
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
4. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
5. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
6. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
7. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
11. Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
Kubitza D; Becka M; Roth A; Mueck W
J Int Med Res; 2012; 40(5):1688-707. PubMed ID: 23206451
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
14. Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Rao N
J Clin Pharmacol; 2011 May; 51(5):784. PubMed ID: 20671297
[No Abstract] [Full Text] [Related]
15. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Boyd RA; Stern RH; Stewart BH; Wu X; Reyner EL; Zegarac EA; Randinitis EJ; Whitfield L
J Clin Pharmacol; 2000 Jan; 40(1):91-8. PubMed ID: 10631627
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression.
Hoffmann P; Beckman D; McLean LA; Yan JH
Toxicol Appl Pharmacol; 2014 Feb; 275(1):36-43. PubMed ID: 24388840
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
19. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]